PNT Pengajuan SEC - POINT Biopharma Global Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1811764

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to POINT Biopharma Global Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

January 8, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39373 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as s
December 27, 2023	SC 13D/A	PNT / POINT Biopharma Global Inc. / SILBER ALLAN C - SC 13D/A Activist Investment SC 13D/A 1 tm2333799d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541 109 (CUSIP Number) Allan C. Silber c/o POINT Biopharma Global Inc. 22 St. Clair Avenue East, Suite 1201,
December 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on December 27, 2023 S-8 POS As filed with the Securities and Exchange Commission on December 27, 2023 Registration No.
December 27, 2023	EX-3.2	AMENDED AND RESTATED BYLAWS POINT BIOPHARMA GLOBAL INC. (a Delaware corporation) ARTICLE I Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF POINT BIOPHARMA GLOBAL INC. (a Delaware corporation) ARTICLE I STOCKHOLDERS Section 1. Annual Meetings. The annual meeting of the stockholders of POINT Biopharma Global Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time,
December 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on December 27, 2023 S-8 POS As filed with the Securities and Exchange Commission on December 27, 2023 Registration No.
December 27, 2023	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 POINT BIOPHARMA GLOBAL INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39373 85-0800493 (State or Other Jurisdiction of Incorporation) (Comm
December 27, 2023	POS AM	As filed with the Securities and Exchange Commission on December 27, 2023 As filed with the Securities and Exchange Commission on December 27, 2023 Registration No.
December 27, 2023	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF POINT BIOPHARMA GLOBAL INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF POINT BIOPHARMA GLOBAL INC. 1. The name of the Corporation is: POINT Biopharma Global Inc. 2. The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is: National Registered Agents, Inc. 3. The na
December 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on December 27, 2023 S-8 POS As filed with the Securities and Exchange Commission on December 27, 2023 Registration No.
December 27, 2023	POS AM	As filed with the Securities and Exchange Commission on December 27, 2023 As filed with the Securities and Exchange Commission on December 27, 2023 Registration No.
December 26, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) POINT BIOPHARMA GLOBAL INC. (Name of Subject Compan SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o
December 26, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 8) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 8) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of C
December 20, 2023	SC 13D/A	PNT / POINT Biopharma Global Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) JAMES KR
December 18, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 7) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 7) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of C
December 18, 2023	EX-99.(A)(5)(F)	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 Exhibit (a)(5)(F) Dec. 18, 2023 For Release: Dec. 18, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 INDIANAPOLIS, Dec. 18, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tende
December 18, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) POINT BIOPHARMA GLOBAL INC. (Name of Subject Compan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing P
December 18, 2023	EX-99.(A)(5)(N)	Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progr Exhibit (a)(5)(N) Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, MA, and INDIANAPOLIS, IN – December 18, 2023 – Lantheus Holdings, Inc.
December 4, 2023	EX-99.(A)(5)(E)	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 Exhibit (a)(5)(E) Dec. 4, 2023 For Release: Dec. 4, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 INDIANAPOLIS, Dec. 4, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender o
December 4, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) POINT BIOPHARMA GLOBAL INC. (Name of Subject Compan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing P
December 4, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se
November 17, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of C
November 17, 2023	EX-99.(A)(5)(D)	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 EX-99.(A)(5)(D) Exhibit (a)(5)(D) Nov. 17, 2023 For Release: Nov. 17, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 INDIANAPOLIS, Nov. 17, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expirati
November 17, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) POINT BIOPHARMA GLOBAL INC. (Name of Subject Compan SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o
November 15, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) POINT BIOPHARMA GLOBAL, INC. (Name of Subject Company (is SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) POINT BIOPHARMA GLOBAL, INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Fil
November 15, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of C
November 15, 2023	EX-99.(A)(5)(C)	Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma Exhibit (a)(5)(C) Nov. 14, 2023 For Release: Immediately Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma INDIANAPOLIS, Nov. 14, 2023 – Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regu
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39
November 8, 2023	EX-99.(A)(5)(B)	Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma Exhibit (a)(5)(B) For Release: Nov.8, 2023 @ 4:45 p.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma INDIANAPOLIS, Nov. 8, 2023 – Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire
November 8, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) POINT BIOPHARMA GLOBAL INC. (Name of Subject Compan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(a) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing P
November 8, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se
November 6, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991to13d07422pnt11062023.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated November 6, 2023 (including amendments thereto) with respect to the Common Stock, par value
November 6, 2023	SC 13D	PNT / POINT Biopharma Global Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) JAMES KRA
November 1, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se
October 27, 2023	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Se
October 27, 2023	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) POINT BIOPHARMA GLOBAL INC. (Name of Subject Compan SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names o
October 13, 2023	EX-99.(A)(1)(C)	Offer to Purchase All Outstanding Shares of Common Stock POINT BIOPHARMA GLOBAL INC. $12.50 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated October 13, 2023 YOSEMITE FALLS ACQUI Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of POINT BIOPHARMA GLOBAL INC.
October 13, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Schedule TO POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identi Exhibit 107 Calculation of Filing Fee Tables Schedule TO POINT BIOPHARMA GLOBAL INC.
October 13, 2023	EX-99.(D)(5)	CONFIDENTIALITY AGREEMENT Exhibit (d)(5) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (the “Agreement”) is made on the last date signed below, (the “Effective Date”), between Eli Lilly and Company and its Affiliates, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285, United States (“Lilly”), and Point Biopharma Global, Inc.
October 13, 2023	SC 14D9	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 73054110
October 13, 2023	EX-99.(A)(1)(D)	Offer to Purchase All Outstanding Shares of Common Stock POINT BIOPHARMA GLOBAL INC. $12.50 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated October 13, 2023 YOSEMITE FALLS ACQUI Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of POINT BIOPHARMA GLOBAL INC.
October 13, 2023	EX-99.(A)(1)(E)	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is being made only by the Offer to Purchase, dated October 13, 2023 (the “Offer to Purchase”) and the rel Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
October 13, 2023	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMI SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (id
October 13, 2023	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL to Tender Shares of Common Stock POINT BIOPHARMA GLOBAL INC. $12.50 per share, net in cash, without interest and less any applicable tax withholding Pursuant to the Offer to Purchase dated October 13, 2023 YOSEMITE FALLS ACQUISI Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of POINT BIOPHARMA GLOBAL INC.
October 13, 2023	EX-99.(A)(1)(A)	Offer to Purchase All Outstanding Shares of Common Stock POINT BIOPHARMA GLOBAL INC. $12.50 per share, net in cash, without interest and less any applicable tax withholding YOSEMITE FALLS ACQUISITION CORPORATION a wholly-owned subsidiary of ELI LILLY Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of POINT BIOPHARMA GLOBAL INC.
October 3, 2023	EX-99.1	Tender and Support Agreement, dated as of October 2, 2023, by and among Eli Lilly and Company, Yosemite Falls Acquisition Corporation and Joe A. McCann (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by POINT Biopharma Global Inc. with the Securities and Exchange Commission on October 3, 2023 (File No. 001-39373)). Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of POINT Biopharma Global Inc
October 3, 2023	EX-99.7	Form of Letter to Key Investigators Exhibit 99.7 Form of Letter to Key Investigators Dear [NAME], Earlier today, it was announced that POINT Biopharma Global Inc. (“POINT”) has agreed to be acquired by Lilly. We are excited to see our pipeline benefit from Lilly’s commitment to oncology, its rich history of innovation and its deep commitment to serving the needs of patients. As a key partner on our clinical trials, we wanted to reac
October 3, 2023	EX-99.4	Media Statement Exhibit 99.4 Media Statement The combination of POINT’s team, infrastructure and capabilities with Lilly’s global resources and experience will accelerate the discovery, development, and global access to the next generation of radiopharmaceuticals. We look forward to a future where patients all over the world can benefit from the new cancer treatment options made possible by the joining of our two
October 3, 2023	EX-99.3	Tender and Support Agreement, dated as of October 2, 2023, by and among Eli Lilly and Company, Yosemite Falls Acquisition Corporation and Neil E. Fleshner (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K filed by POINT Biopharma Global Inc. with the Securities and Exchange Commission on October 3, 2023 (File No. 001-39373)). Exhibit 99.3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of POINT Biopharma Global Inc
October 3, 2023	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 POINT BIOPHARMA GLOBAL INC. (Name of Subject Company (issuer)) YOSEMITE FALLS ACQUISITION CORPORATION (Offeror) a wholly-owned subsidiary of ELI LILLY AND COMPANY (Parent of Offeror) (Names of Filing Persons (identifyin
October 3, 2023	EX-99.1	Email to employees Exhibit 99.1 Email to employees Dear Team, A few moments ago, it was announced (link to press release) that POINT Biopharma Global Inc. has entered into a definitive agreement to be acquired by Lilly, one of the largest and most well-respected pharmaceutical companies in the world. As the news sinks in and the details are explained, I hope that you will come to feel as excited about our next chapt
October 3, 2023	EX-99.4	Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies Exhibit 99.4 Oct. 2, 2023 For Release: Oct. 3, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Daniel Pearlstein; [email protected] (POINT Investors) Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies INDIANAPOLIS, Oct. 3, 2023 –
October 3, 2023	EX-99.4	Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies Exhibit 99.4 Oct. 2, 2023 For Release: Oct. 3, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Daniel Pearlstein; [email protected] (POINT Investors) Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies INDIANAPOLIS, Oct. 3, 2023 –
October 3, 2023	EX-2.1	Agreement and Plan of Merger, dated as of October 2, 2023, by and among Eli Lilly and Company, Yosemite Falls Acquisition Corporation and POINT Biopharma Global Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by POINT Biopharma Global Inc. with the Securities and Exchange Commission on October 3, 2023 (File No. 001-39373)). Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, among ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION and POINT BIOPHARMA GLOBAL INC. Table of Contents Page Article I Definitions 2 Section 1.01 Definitions 2 Section 1.02 Interpretation and Rules of Construction 12 Article II The Offer 13 Section 2.01 The Offer 13 Section 2.02 Company Actions 15 Article III The M
October 3, 2023	EX-99.8	2 Exhibit 99.8 The following social media posts were first used on October 3, 2023: Point Biopharma Global Inc. (the “Company”) posted the following message on LinkedIn [URL: https://www.linkedin.com/feed/update/urn:li:activity:7114965022941872129/]: “Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Read the full release as it contains impo
October 3, 2023	EX-2.1	AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION POINT BIOPHARMA GLOBAL INC. Table of Contents Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, among ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION and POINT BIOPHARMA GLOBAL INC. Table of Contents Page Article I Definitions 2 Section 1.01 Definitions 2 Section 1.02 Interpretation and Rules of Construction 12 Article II The Offer 13 Section 2.01 The Offer 13 Section 2.02 Company Actions 15 Article III The M
October 3, 2023	EX-99.2	TENDER AND SUPPORT AGREEMENT Exhibit 99.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of POINT Biopharma Global Inc
October 3, 2023	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Subject Company) POINT Biopharma Global Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 73054110
October 3, 2023	EX-99.6	Form of Letter to Business Partners Exhibit 99.6 Form of Letter to Business Partners Dear [NAME], Earlier today, it was announced that POINT Biopharma Global Inc. (“POINT”) has agreed to be acquired by Lilly. The transaction is expected to close by the end of this year. We are excited to see our pipeline benefit from the resources, expertise and global reach of Lilly’s organization. As a valued supplier / partner of POINT, we wanted
October 3, 2023	EX-99.3	Investor FAQ Exhibit 99.3 Investor FAQ 1. When will more information about the transaction and negotiations be available? · Lilly will initiate the tender offer process with a public filing of a tender offer document, and POINT Biopharma Global Inc. (“POINT”) will make its own public filing at the same time. Please review these documents for additional background to the transaction. 2. Why sell now? · Our Boar
October 3, 2023	EX-99.3	TENDER AND SUPPORT AGREEMENT Exhibit 99.3 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of POINT Biopharma Global Inc
October 3, 2023	EX-99.2	Employee FAQ Exhibit 99.2 Employee FAQ 1. What was announced today? · Lilly and POINT Biopharma Global Inc. (“POINT”) announced an agreement for the acquisition of POINT for $12.50 per share, or approximately $1.4 billion. 2. Why does Lilly want to acquire POINT? · Lilly was looking for opportunities to expand the breadth of its oncology portfolio and recognized POINT’s leadership in the discovery, development
October 3, 2023	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 POINT BIOPHARMA G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 POINT BIOPHARMA GLOBAL INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39311 85-0800493 (State or Other Jurisdiction of Incorporation) (Commis
October 3, 2023	EX-99.5	Form of Letter for Upcoming Meetings Exhibit 99.5 Form of Letter for Upcoming Meetings Dear [NAME], It was announced that POINT Biopharma Global Inc. (“POINT”) has agreed to be acquired by Lilly. Due to the announcement, POINT’s management will not be participating at [upcoming investor event] and must cancel their meeting with you. For any questions on the proposed acquisition, please reference the press release and related SEC fili
October 3, 2023	SC 13D/A	PNT / POINT Biopharma Global Inc / SILBER ALLAN C - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541 109 (CUSIP Number) Allan C. Silber c/o POINT Biopharma Global Inc. 22 St. Clair Avenue East, Suite 1201, Toronto, Ontario, M4T 2S3, Canada (833) 5
October 3, 2023	EX-99.1	TENDER AND SUPPORT AGREEMENT Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of POINT Biopharma Global Inc
October 3, 2023	EX-99.1	Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies EX-99.1 Exhibit 99.1 For Release: Oct. 3, 2023 @ 6:45 a.m. ET Refer to: Jordan Bishop; [email protected]; 317-473-5712 (Media) Joe Fletcher; [email protected]; 317-296-2884 (Investors) Daniel Pearlstein; [email protected] (POINT Investors) Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies INDIANAPOLIS, Oct. 3, 2023 –
October 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 POINT BIOPHARMA G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 POINT BIOPHARMA GLOBAL INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39311 85-0800493 (State or Other Jurisdiction of Incorporation) (Commis
October 3, 2023	EX-99.2	Tender and Support Agreement, dated as of October 2, 2023, by and among Eli Lilly and Company, Yosemite Falls Acquisition Corporation and Allan Charles Silber (incorporated by reference to Exhibit 99.2 to the Current Report on Form 8-K filed by POINT Biopharma Global Inc. with the Securities and Exchange Commission on October 3, 2023 (File No. 001-39373)). Exhibit 99.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of POINT Biopharma Global Inc
August 14, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Calculation of Filing Fee Tables Form S-8 (Form Type) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0
August 14, 2023	EX-10.2	Amendment No. 1 dated April 17, 2023 to Sublicense Agreement dated November 14, 2019 between POINT Theranostics Inc. and Scintomics GmbH. Exhibit 10.2 First Amendment to the Exclusive Sublicense Agreement between Point Biopharma Inc. a Delaware Corporation with its registered agent National Registered Agents, Inc. 160 Greentree Drive - Suite 101 Dover, DE 19904 U.S.A. - hereinafter called "POINT" - and Scintomics GmbH Jahnplatz 4 82166 Gräfelfing Germany - hereinafter called "SCI" - SCI and POINT are referred to individually or join
August 14, 2023	S-8	As filed with the Securities and Exchange Commission on August 14, 2023 As filed with the Securities and Exchange Commission on August 14, 2023 Registration No.
August 14, 2023	EX-10.3	Amendment No. 2 dated April 17, 2023 to Sublicense Agreement dated November 14, 2019 between POINT Theranostics Inc. and Scintomics GmbH. Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL Second Amendment to the Exclusive Sublicense Agreement between Point Biopharma Inc. a Delaware Corporation with its registered agent National Registered Agents, Inc. 160 Greent
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39311 P
August 14, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 14, 2023 (August 14, 2023) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311
August 14, 2023	EX-99.1	POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Enrollment in PNT2002's SPLASH trial is complete and top line data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2 POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Enrollment in PNT2002's SPLASH trial is complete and top line data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024 Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212 INDIANAPOLIS, INDIANA – August 14, 2023 – POINT Biopharma Global Inc.
August 14, 2023	EX-10.4	Employment Agreement dated May 3, 2023, by and between POINT Biopharma Corp. and Dr. Neil Fleshner Personal & Confidential Neil Fleshner 610 University Ave Suite 3-130, Toronto, ON M5G 1Z5 April 28, 2023 Dear Neil: On behalf of POINT Biopharma (the “Company”), I am pleased to offer you regular fulltime employment as a member of our team.
August 3, 2023	EX-16.1	Letter from Armanino LLP, dated August 3, 2023 Armanino LLP 50 West San Fernando Street Suite 500 San Jose, CA 95113-2438 408 200 6400 main 408 200 6401 fax armanino.
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2023 (July 28, 2023) PO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2023 (July 28, 2023) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Co
June 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 (June 12, 2023) POI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 (June 12, 2023) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Com
June 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2023 (June 1, 2023) POINT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2023 (June 1, 2023) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commi
May 15, 2023	EX-10.1	Facility Agreement dated as of February 2, 2023 and effective as of April 1, 2023 between University Health Network and POINT Biopharma Corp. Exhibit 10.1 FACILITY AGREEMENT This Facility Agreement (the “Facility Agreement”) is entered into as of February 2, 2023 (the “Execution Date”) and effective as of April 1, 2023 (the “Effective Date”) between the following parties: UNIVERSITY HEALTH NETWORK An Ontario not-for-profit corporation incorporated under the University Health Network Act, 1997, having a business office at 101 College Str
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39311
May 1, 2023	ARS	2022 Annual Report POINT BIOPHARMA GLOBAL INC Dr. Joe McCann MESSAGE FROM THE CEO Dr. Joe McCann Chief Executive Officer Dear fellow stockholders: 2022 was another year of achievements at POINT. We completed enrollment for the randomization phase of pointbiopharma2022annual 2022 Annual Report POINT BIOPHARMA GLOBAL INC Dr. Joe McCann MESSAGE FROM THE CEO Dr. Joe McCann Chief Executive Officer Dear fellow stockholders: 2022 was another year of achievements at POINT. We completed enrollment for the randomization phase of PNT2002’s SPLASH phase 3 registrational trial, and also selected the lead for PNT2001, our next-generation actinium-225 PSMA-
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [ x ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permi
March 27, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39311 P
March 27, 2023	EX-10.9	Form of Performance Stock Unit Award under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan Exhibit 10.9 PERFORMANCE STOCK UNIT AWARD AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Employees) Name of Grantee: No. of Performance Stock Units Grant Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc. (the “Company”) hereby grants an award of the number of perform
March 27, 2023	EX-10.17	First Amendment dated November 8, 2022 to the Exclusive License and Commercialization Agreement dated December 16, 2020 between POINT; the Canadian Molecular Probe Consortium; the Centre for Probe Development and Commercialization; and The University Health Network Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. UHN Ref#: 2020-2785 FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT This First Amendment to the Exclusive License and Commercialization Agreement (this “
February 14, 2023	SC 13G/A	PNT / POINT Biopharma Global Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga107422pnt02142023.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par
February 7, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2023 (February 2, 2023) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-3931
November 22, 2022	SC 13D/A	PNT / POINT Biopharma Global Inc. / SILBER ALLAN C - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541 109 (CUSIP Number) Allan C. Silber c/o POINT Biopharma Global Inc. 22 St. Clair Avenue East, Suite 1201, Toronto, Ontario, M4T 2S3, Canada (833) 5
November 14, 2022	EX-10.2	License and Collaboration Agreement (PNT-2003) dated November 11, 2022 between the Company and Lantheus Three, LLC EX-10.2 3 pnt-2003licenseandcollab.htm EX-10.2 Exhibit 10.2 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT BETWEEN POINT BIOPHARMA, INC.,
November 14, 2022	EX-10.1	License and Collaboration Agreement (PNT-2002) dated November 11, 2022 between the Company and Lantheus Two, LLC Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT BETWEEN POINT BIOPHARMA, INC., LANTHEUS TWO, LLC AND, FOR PURPOSES OF SECTION
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39
September 26, 2022	SC 13G	PNT / POINT Biopharma Global Inc. / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Numb
September 26, 2022	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 26, 2022 with respect to the Common Stock, par value $0.0001 per share, of POINT Biopharma Global Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accord
September 26, 2022	SC 13D/A	PNT / POINT Biopharma Global Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* POINT BIOPHARMA GLOBAL INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Pe
September 16, 2022	SC 13D/A	PNT / POINT Biopharma Global Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* POINT BIOPHARMA GLOBAL INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Pe
September 14, 2022	EX-99.1	POINT Biopharma Prices Public Offering of Common Stock Exhibit 99.1 POINT Biopharma Prices Public Offering of Common Stock September 13, 2022 ? INDIANAPOLIS, INDIANA ? POINT Biopharma Global Inc. (NASDAQ: PNT) (the ?Company? or ?POINT?), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing of its public offering of 13,900,000 shares of Common Stock at a public offering p
September 14, 2022	424B5	PROSPECTUS SUPPLEMENT (to Prospectus dated July 11, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. 333-265981 PROSPECTUS SUPPLEMENT (to Prospectus dated July 11, 2022) 13,900,000 Shares POINT Biopharma Global Inc. Common Stock We are offering 13,900,000 shares of our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol ?PNT?. On September 12, 2022, the last reported sale price of our common stock on the Nasdaq C
September 14, 2022	EX-1.1	Purchase Agreement dated September 13, 2022 by and among the Company, Piper Sandler & Co. and Guggenheim Securities, LLC EX-1.1 2 exhibit11-8xk.htm EX-1.1 Exhibit 1.1 Execution Version 13,900,000 Shares1 POINT Biopharma Global Inc. Common Stock PURCHASE AGREEMENT September 13, 2022 PIPER SANDLER & CO. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Guggenheim Securities,
September 14, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2022 (September 13, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39311 85-0800493 (State or other jurisdiction o
September 13, 2022	EX-99.1	POINT Biopharma Announces Proposed Public Offering of Common Stock POINT Biopharma Announces Proposed Public Offering of Common Stock September 13, 2022 ? INDIANAPOLIS, INDIANA ? POINT Biopharma Global Inc.
September 13, 2022	424B5	Subject to Completion, dated September 13, 2022 PRELIMINARY PROSPECTUS SUPPLEMENT (to Prospectus dated July 11, 2022) The information in this preliminary prospectus supplement is not complete and may be changed.
September 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): (September 13, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commission F
September 12, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 12, 2022 (September 10, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-
September 12, 2022	EX-99.1	POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022 Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates includi POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022 Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.
September 12, 2022	EX-99.2	Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH Presented at the European Society for Medical Oncology (ESMO) Congress, Sep EX-99.2 3 esmo2022poster1400pfina.htm EX-99.2 Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH Presented at the European Society for Medical Oncology (ESMO) Congress, September 9–13, 2022 Paris, France. Corresponding author: [email protected] BACKGROUND ⚫ The
September 6, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2022 (September 4, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39
September 6, 2022	EX-99.1	POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial Poster #1400P will be presented on Sunday, September 11 by Dr.
August 29, 2022	SC 13D/A	PNT / POINT Biopharma Global Inc. / RA CAPITAL MANAGEMENT, L.P. - POINT BIOPHARMA GLOBAL INC. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* POINT BIOPHARMA GLOBAL INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Pe
August 12, 2022	S-8	As filed with the Securities and Exchange Commission on August 12, 2022 As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39311 P
August 12, 2022	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables Form S-8 (Form Type) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0
August 12, 2022	EX-10.1	Fourth Amendment dated May 6, 2022 to Exclusive Sublicense Agreement dated April 2, 2020 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. FOURTH AMENDMENT TO EXCLUSIVE FAPi SUBLICENSE AGREEMENT This Fourth Amendment to Exclusive Sublicense Agreement (this ?Amendment?) dated May 6, 2022, is entered into by and be
July 11, 2022	424B3	Up to 53,211,039 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-258325 PROSPECTUS Up to 53,211,039 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus (the ?Selling Securityholders?), or any of their pledgees, donees, assignees and successors-in-interest (?permitted transferees?), of (i) up to an aggregate of 16,500
July 7, 2022	CORRESP	POINT Biopharma Global Inc. 4850 West 78th Street, Indianapolis, IN 46268 July 7, 2022 POINT Biopharma Global Inc. 4850 West 78th Street, Indianapolis, IN 46268 July 7, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-4041 Attention: Jason Drory Re: POINT Biopharma Global Inc. Registration Statement on Form S-3 File No. 333-265981 Request for Acceleration Requested Date: July 11, 2022 Re
July 1, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form type) POINT BIOPHARMA GLOBAL INC.
July 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) POINT BIOPHARMA GLOBAL INC.
July 1, 2022	S-3	As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 No. 333-[l] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-0800493 (State or other jurisdiction of incorporation or organization) (Primary St
July 1, 2022	EX-1.2	, 2022 by and between POINT Biopharma Global, Inc. and Piper Sandler Exhibit 1.2 POINT BIOPHARMA GLOBAL INC. EQUITY DISTRIBUTION AGREEMENT July 1, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), POINT Biopharma Global Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Pip
July 1, 2022	POS AM	As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 No. 333-258325 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 TO Form S-1 ON Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-0800493 (State or other jurisdict
July 1, 2022	EX-4.6	Form of Senior Indenture between POINT Biopharma Global, Inc. and one or more trustees to be named. Exhibit 4.6 POINT BIOPHARMA GLOBAL INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS ARTICLE I DEFINITIONS 5 Section 1.01. Definitions of Terms 5 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.01. Designation and Terms of Securities 8 Section 2.02. Form of Securities and Trustee?s Certificate
July 1, 2022	EX-4.7	Form of Subordinated Indenture between POINT Biopharma Global, Inc. and one or more trustees to be named. Exhibit 4.7 POINT BIOPHARMA GLOBAL INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certific
June 3, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2022 (June 2, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commi
May 16, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 (May 11, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commi
May 16, 2022	EX-99.1	POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-? Targeted Clinical Program A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004?s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy May 16, 2022 ? INDIANAPOLIS, INDIANA ? POINT Biopharma Global Inc.
May 16, 2022	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) (to prospectus dated March 31, 2022) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 3 (this ?prospectus supplement?) amends and supplements the prospectus dated March 31, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Stateme
May 16, 2022	EX-99.1	POINT Biopharma Global Inc. press release dated May 16, 2022 POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-? Targeted Clinical Program A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004?s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy May 16, 2022 ? INDIANAPOLIS, INDIANA ? POINT Biopharma Global Inc.
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39311
May 13, 2022	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated March 31, 2022) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 2 (this ?prospectus supplement?) amends and supplements the prospectus dated March 31, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Stateme
May 12, 2022	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) (to prospectus dated March 31, 2022) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 1 (this ?prospectus supplement?) amends and supplements the prospectus dated March 31, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Stateme
May 12, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 (May 6, 2022) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commis
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [ x ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permi
March 31, 2022	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS File Pursuant to Rule 424(b)(3) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus (the ?Selling Securityholders?), or any of their pledgees, donees, assignees and successors-in-interest (?permitted transferees?), of (i) up to an aggregate of 16,500,
March 25, 2022	EX-99.1	POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 the EX-99.1 2 fiscal2021earningsrelease.htm EX-99.1 POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FA
March 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39311 P
March 25, 2022	EX-10.20	Employment Agreement dated as of December 1, 2021, by and between POINT Biopharma USA Inc. and Justyna Kelly (incorporated by reference to Exhibit 10.20 to the Annual Report on Form 10-K for the year ending December 31, 2021). EX-10.20 3 exhibit1020-10xk.htm EX-10.20 Exhibit 10.20 POINT Biopharma USA Inc. 4850 West 78th St. Indianapolis, Indiana 46268 POINT Biopharma USA Inc. Employment Agreement POINT Biopharma USA Inc. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Justyna Kelly Dear Justyna: Re: Terms of Employment of Justyna Kelly (“you” or the “Emp
March 25, 2022	POS AM	As filed with the Securities and Exchange Commission on March 25, 2022 As filed with the Securities and Exchange Commission on March 25, 2022 No. 333-258325 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-0800493 (State or other jurisdiction of inc
March 25, 2022	EX-4.1	Exhibit 4.1 Exhibit 4.1 1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, POINT Biopharma Global Inc. (?POINT,? ?us,? ?our,? ?we,? or the ?Company?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1034, as amended (the ?Exchange Act?), which is our Common Stock (as defined bel
March 25, 2022	EX-10.25	Consulting Agreement effective January 1, 2022 by and between POINT Biopharma Inc. and Dr. Neil Fleshner. Exhibit 10.25 CONSULTING AGREEMENT This Consulting Agreement (this "Agreement") is entered into as of January 1, 2022 ("Effective Date") for a term ending on December 31, 2022 ("End Date") by and between POINT Biopharma Inc., a corporation duly incorporated under the laws of Delaware ("POINT" or the "Company"), and between Dr. Neil Fleshner, 1510789 Ontario Inc. with a registered office at 610 Uni
March 25, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2022 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commission File Nu
March 25, 2022	EX-10.26	(incorporated by reference to Exhibit 10.26 to the Annual Report on Form 10-K for the year ended December 31, Exhibit 10.26 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL (Sub-)License Agreement between Point Theranostics Inc. a Delaware Corporation with its registered agent National Registered Agents, Inc. 160 Greentree Drive - Suite 101 Dover
February 25, 2022	EX-99.1	Point BioPharma Global Investor Presentation dated February 25, 2022 Accelerating Precision MedicineTM 1 February 2022 Investor Presentation NASDAQ: PNT Accelerating Precision Medicine? Accelerating Precision MedicineTM Legal Disclaimer 2 Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to ?we,? ?our,? ?us,? ?POINT,? or the ?Company? refer to POINT Biopharma Global Inc.
February 25, 2022	EX-99.1	Accelerating Precision MedicineTM 1 February 2022 Investor Presentation NASDAQ: PNT Accelerating Precision Medicine™ Accelerating Precision MedicineTM Legal Disclaimer 2 Except as otherwise indicated or unless the context otherwise requires, all refe EX-99.1 2 exhibit991-pointbiopharm.htm EX-99.1 Accelerating Precision MedicineTM 1 February 2022 Investor Presentation NASDAQ: PNT Accelerating Precision Medicine™ Accelerating Precision MedicineTM Legal Disclaimer 2 Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “us,” “POINT,” or the “Company” refer to POINT Biopharma Gl
February 25, 2022	EX-99.2	POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid- Winter & ACNM Annual Meeting Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid- Winter & ACNM Annual Meeting Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied Red marrow dosimetry was well below critical thresholds, enabling a potential oppor- tunity for combination therapy February 25, 2022 ? INDIANAPOLIS, INDIANA ? POINT Biopharma Global Inc.
February 25, 2022	EX-99.2	Press Release issued February 25, 2022 POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid- Winter & ACNM Annual Meeting Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied Red marrow dosimetry was well below critical thresholds, enabling a potential oppor- tunity for combination therapy February 25, 2022 ? INDIANAPOLIS, INDIANA ? POINT Biopharma Global Inc.
February 25, 2022	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 7 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 5, 2021.) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 7 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
February 25, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):February 25, 2022 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commission File
February 15, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2022 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39311 (Commission File
February 15, 2022	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 6 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 5, 2021.) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 6 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
February 15, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* POINT Biopharma Global Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 730541 109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 15, 2022	EX-99.1	AGREEMENT EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.
February 14, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 POINT Biopharma Global Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 730541109 (CUSIP Numbe
February 14, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / RIVERVIEW GROUP LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) POINT BIOPHARMA GLOBAL INC. (formerly Therapeutics Acquisition Corp.) (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 730541109 (CUSIP Number) DECEMBER 31, 2021 (Date of event which requires filing of this stateme
February 14, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - PNT AS OF 12/31/2021 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) POINT BIOPHARMA GLOBAL INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 730541109 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc
February 14, 2022	SC 13G/A	Therapeutics Acquisition Corp. Class A / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* POINT Biopharma Global Inc. Common Stock, $0.0001 par value (Title of Class of Securities) 88339T103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
February 11, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / Avoro Capital Advisors LLC - POINT BIOPHARMA GLOBAL INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* POINT Biopharma Global Inc. (f/k/a Therapeutics Acquisition Corp.) (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Ch
February 11, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 7, 2022	SC 13G/A	PNT / POINT Biopharma Global Inc. / FRANKLIN RESOURCES INC Passive Investment poin21a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 730541109 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* POINT BIOPHARMA GLOBAL INC. (Name of Issuer) Common Stock (Title of Class of Securities) 730541109 (CUSIP Number) December 31, 2021 (Date of Event Which Require
February 4, 2022	SC 13G/A	Therapeutics Acquisition Corp. Class A / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* POINT Biopharma Global Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 88339T103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
December 10, 2021	EX-10.3	Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan EX-10.3 4 exhibit103.htm EX-10.3 Exhibit 10.3 FORM OF INCENTIVE STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc
December 10, 2021	EX-10.2	Revised Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan ( Exhibit 10.2 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Non-Employee Directors) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the ?Plan?), POINT Biopharma Global Inc. (t
December 10, 2021	EX-10.1	-Qualified Stock Option Agreement under the POINT Exhibit 10.1 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Employees) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc. (the “Company”)
December 10, 2021	EX-10.3	Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan Exhibit 10.3 FORM OF INCENTIVE STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc. (the “Company”) hereby grants t
December 10, 2021	EX-10.2	Revised Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan ( EX-10.2 3 exhibit102.htm EX-10.2 Exhibit 10.2 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Non-Employee Directors) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”
December 10, 2021	EX-10.1	-Qualified Stock Option Agreement under the POINT EX-10.1 2 exhibit101.htm EX-10.1 Exhibit 10.1 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Employees) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biop
December 10, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 10, 2021 (December 9, 2021) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-393
December 10, 2021	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 5 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 5, 2021.) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 5 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
December 1, 2021	EX-99.1	Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains
December 1, 2021	EX-99.1	POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes Justyna Kelly promoted to COO, Dr.
December 1, 2021	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 4 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 5, 2021.) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 4 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
December 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 1, 2021 (November 25, 2021) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-393
December 1, 2021	EX-99	Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains
November 19, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2021 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39311 85-0800493 (State or other jurisdiction of incorporation) (Comm
November 19, 2021	EX-99.1	Accelerating Precision Medicine™ Nasdaq: PNT Accelerating Precision Medicine™ November 2021 Accelerating Precision Medicine™ Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “ Accelerating Precision Medicine? Nasdaq: PNT Accelerating Precision Medicine? November 2021 Accelerating Precision Medicine? Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to ?we,? ?our,? ?us,? ?POINT,? or the ?Company? refer to POINT Biopharma Global Inc.
November 12, 2021	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 5, 2021.) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 3 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
November 12, 2021	EX-10.4	Third Amendment to Exclusive Sublicense Agreement, dated September 24, 2021, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. THIRD AMENDMENT TO EXCLUSIVE SUBLICENSE AGREEMENT This Third Amendment to Exclusive Sublicense Agreement (
November 12, 2021	EX-10.4	Third Amendment to Exclusive Sublicense Agreement, dated September 24, 2021, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. THIRD AMENDMENT TO EXCLUSIVE SUBLICENSE AGREEMENT This Third Amendment to Exclusive Sublicense Agreement (
November 12, 2021	EX-10.3	Second Amendment to Exclusive Sublicense Agreement, dated January 5, 2021 to be effective as of December 31, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc. EX-10.3 4 exhibit103-pnt2004fapili.htm EX-10.3 Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. SECOND AMENDMENT TO EXCLUSIVE SUBLICENSE AGREEMENT This Sec
November 12, 2021	EX-10.1	Exclusive Sublicense Agreement, dated April 2, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. EXCLUSIVE SUBLICENSE AGREEMENT This Exclusive Sublicense Agreement (together with its Appendices, the “Agr
November 12, 2021	EX-10.2	First Amendment to Exclusive Sublicense Agreement, dated April 14, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. FIRST AMENDMENT TO EXCLUSIVE SUBLICENSE AGREEMENT This First Amendment of the Exclusive Sublicense Agreeme
November 12, 2021	EX-10.1	Exclusive Sublicense Agreement, dated April 2, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. EXCLUSIVE SUBLICENSE AGREEMENT This Exclusive Sublicense Agreement (together with its Appendices, the “Agr
November 12, 2021	EX-10.3	Second Amendment to Exclusive Sublicense Agreement, dated January 5, 2021 to be effective as of December 31, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. SECOND AMENDMENT TO EXCLUSIVE SUBLICENSE AGREEMENT This Second Amendment to Exclusive Sublicense Agreement
November 12, 2021	EX-10.2	First Amendment to Exclusive Sublicense Agreement, dated April 14, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc. Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. [***] = Indicates confidential information omitted from the exhibit. FIRST AMENDMENT TO EXCLUSIVE SUBLICENSE AGREEMENT This First Amendment of the Exclusive Sublicense Agreeme
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number: 001-39
September 28, 2021	424B3	Up to 53,211,039 Shares of Common Stock PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated August 5, 2021.) Registration No. 333-258325 Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 2 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
September 28, 2021	EX-99.1	POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiat EX-99.1 2 tm2128636d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022 September 28th, 2021 – INDIAN
September 28, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2021 (September 24, 2021) POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39311 85-0800493 (State or other jurisdiction o
September 14, 2021	SC 13D/A	PNT / POINT Biopharma Global Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13D/A Activist Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
August 30, 2021	S-8	As filed with the Securities and Exchange Commission on August 30, 2021 As filed with the Securities and Exchange Commission on August 30, 2021 No. 333-[?] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-0800493 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Em
August 13, 2021	424B3	Up to 53,211,039 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-258325 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated August 5, 2021.) Up to 53,211,039 Shares of Common Stock This prospectus supplement no. 1 (this ?prospectus supplement?) amends and supplements the prospectus dated August 5, 2021 (as supplemented or amended from time to time, the ?Prospectus?) which forms a part of our Registration Statem
August 13, 2021	EX-99.1	POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update Strengthened the Company’s balance sheet by completing the business combination with Therapeutics Acquisition Corp (“RACA”), with gross proceeds from the trans Exhibit 99.1 POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update Strengthened the Company?s balance sheet by completing the business combination with Therapeutics Acquisition Corp (?RACA?), with gross proceeds from the transaction totaling approximately $286.7 million Completion of enrollment of the 25-patient safety and dosimetry lead-in in the Phase 3 SPLAS
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2021 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39311 85-0800493 (State or other jurisdiction of incorporation) (Commis
August 5, 2021	424B3	Up to 53,211,039 Shares of Common Stock TABLE OF CONTENTS ? Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-258325? PROSPECTUS Up to 53,211,039 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholders named in this prospectus (the ?Selling Securityholders?), or any of their pledgees, donees, assignees and successors-in-interest (?permitted transferees?), of (i) up to
August 3, 2021	CORRESP	POINT BIOPHARMA GLOBAL INC. 4850 West 78th Street, Indianapolis, IN 46268 POINT BIOPHARMA GLOBAL INC. 4850 West 78th Street, Indianapolis, IN 46268 August 3, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4041 Attention: Jane Park Re: POINT Biopharma Global Inc. Registration Statement on Form S-1, File No. 333-258325 (the ?Registration Statement?) Ladies and Gentlemen: On behalf of
July 30, 2021	S-1	Form S-1 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 30, 2021 No.
July 20, 2021	SC 13G	PNT / POINT Biopharma Global Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* POINT Biopharma Global Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 730541109 (CUSIP Number) July 20, 2021 ** (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
July 12, 2021	SC 13D	PNT / POINT Biopharma Global Inc. / SILBER ALLAN C - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 POINT Biopharma Global Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 730541 109 (CUSIP Number) Allan C. Silber c/o POINT Biopharma Global Inc. 22 St. Clair Avenue East, Suite 1201, Toronto, Ontario, M4T 2S3, Canada (833) 544
July 1, 2021	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 001-39311 85-0800493 (State or other jurisdiction of incorporation) (Commissi
July 1, 2021	EX-10.2	Amended and Restated Registration and Stockholder Rights Agreement, dated June 30, 2021, by and among Therapeutics Acquisition Holdings LLC and the stockholders party thereto (incorporated by reference to Exhibit 10.2 to the Form 8-K filed by the Company on July 1, 2021). Exhibit 10.2 AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of June 30, 2021, is made and entered into by and among POINT Biopharma Global Inc., a Delaware corporation (the ?Company?) (formerly known as Therapeutics Acquisition Corp. (d/b/a Research Alliance Corp. I)), Therapeut
July 1, 2021	EX-21.1	List of Subsidiaries EX-21.1 13 tm2121132d1ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries Point Biopharma Inc. (Delaware) POINT Biopharma Corp. (Ontario) POINT Biopharma USA Inc. (Delaware) West 78th Street, LLC (Indiana)
July 1, 2021	EX-10.7	Form of Restricted Stock Unit Award Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Directors) (incorporated by reference to Exhibit 10.7 to the Form 8-K filed by the Company on July 1, 2021). EX-10.7 9 tm2121132d1ex10-7.htm EXHIBIT 10.7 Exhibt 10.7 FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Non-Employee Directors) Name of Grantee: No. of Restricted Stock Units Grant Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc.
July 1, 2021	EX-10.8	Form of Incentive Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Form 8-K filed by the Company on July 1, 2021). EX-10.8 10 tm2121132d1ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 FORM OF INCENTIVE STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biophar
July 1, 2021	EX-3.2	By-laws of POINT Biopharma Global Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed by the Company on July 1, 2021). Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF POINT BIOPHARMA GLOBAL INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place
July 1, 2021	EX-10.4	Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Employees) (incorporated by reference to Exhibit 10.4 to the Form 8-K filed by the Company on July 1, 2021). Exhibit 10.4 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Employees) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the ?Plan?), POINT Biopharma Global Inc. (the ?Company?)
July 1, 2021	EX-10.5	Form of Non-Qualified Stock Option Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Directors) (incorporated by reference to Exhibit 10.5 to the Form 8-K filed by the Company on July 1, 2021). EX-10.5 7 tm2121132d1ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Non-Employee Directors) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof
July 1, 2021	EX-10.6	Form of Restricted Stock Unit Award Agreement under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (Employees) (incorporated by reference to Exhibit 10.6 to the Form 8-K filed by the Company on July 1, 2021). EX-10.6 8 tm2121132d1ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN (Employees) Name of Grantee: No. of Restricted Stock Units Grant Date: Pursuant to the POINT Biopharma Global Inc. 2021 Equity Incentive Plan as amended through the date hereof (the “Plan”), POINT Biopharma Global Inc. (the “Compan
July 1, 2021	EX-3.1	Certificate of Incorporation of POINT Biopharma Global Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Company on July 1, 2021). Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF POINT BIOPHARAMA GLOBAL INC. ARTICLE I The name of the Corporation is POINT Biopharma Global Inc. ARTICLE II The address of the Corporation?s registered office in the State of Delaware is 1209 Orange Street in the city of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trus
July 1, 2021	EX-10.3	POINT Biopharma Global Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by the Company on July 1, 2021). EX-10.3 5 tm2121132d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 POINT BIOPHARMA GLOBAL INC. 2021 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, non-employee directors and consultants of POINT Biopharma Glob
July 1, 2021	EX-99.1	Point Biopharma Global Inc. Unaudited pro forma condensed combined financial statements UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.1 14 tm2121132d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Point Biopharma Global Inc. Unaudited pro forma condensed combined financial statements UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction Point Biopharma Inc. (“Old POINT”) was incorporated under the General Corporation Law of the State of Delaware on September 18, 2019 under the name of Point Theranostics Inc. befo
July 1, 2021	EX-10.18	Form of Indemnification Agreement (incorporated by reference to Exhibit 10.18 to the Form 8-K filed by the Company on July 1, 2021). EX-10.18 11 tm2121132d1ex10-18.htm EXHIBIT 10.18 Exhibit 10.18 POINT Biopharma global inc. indemnification agreement Indemnitee: Effective Date: Effective as of the Effective Date, Indemnitee and POINT Biopharma Global Inc., a Delaware corporation (“Company”), enter into this Indemnification Agreement (the “Agreement”). WHEREAS, highly competent persons have become more reluctant to serve corporat
July 1, 2021	EX-16.1	Letter to SEC from WithumSmith+Brown, PC (incorporated by reference to Exhibit 16.1 to the Form 8-K filed by the Company on July 1, 2021). Exhibit 16.1 June 30, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read POINT Biopharma Global Inc.’s (formally known as Therapeutics Acquisition Corp.) statements included under Item 4.01 of its Form 8-K dated June 30, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we
June 30, 2021	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2021 THERAPEUTICS ACQUISITION CORP.
June 30, 2021	SC 13D	/ Therapeutics Acquisition Corp. Class A / RA CAPITAL MANAGEMENT, L.P. - THERAPEUTICS ACQUISITION CORP. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Therapeutics Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 88339T103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.
June 21, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2021 THERAPEUTICS ACQUISITION CORP.
June 21, 2021	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2021 THERAPEUTICS ACQUISIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2021 THERAPEUTICS ACQUISITION CORP.
June 9, 2021	EX-99.1	Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021 Exhibit 99.1 Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021 June 9, 2021 ?BOSTON, MA ? Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I, a Delaware corporation (?the Company?) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333
June 9, 2021	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2021 THERAPEUTICS ACQUISITI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2021 THERAPEUTICS ACQUISITION CORP.
June 9, 2021	EX-99.1	Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021 EX-99.1 2 tm2118501d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021 June 9, 2021 –BOSTON, MA – Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its regist
June 9, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2021 THERAPEUTICS ACQUISITION CORP.
June 9, 2021	424B3	PROXY STATEMENT FOR SPECIAL MEETING OF THERAPEUTICS ACQUISITION CORP. PROSPECTUS FOR 60,240,279 SHARES OF COMMON STOCK OF THERAPEUTICS ACQUISITION CORP. TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3) ? ?Registration No. 333-254600? PROXY STATEMENT FOR SPECIAL MEETING OF THERAPEUTICS ACQUISITION CORP. PROSPECTUS FOR 60,240,279 SHARES OF COMMON STOCK OF THERAPEUTICS ACQUISITION CORP. ? The board of directors of Therapeutics Acquisition Corp., a Delaware corporation, d/b/a Research Alliance Corp. I (?RACA?), has unanimously approved the transact
June 8, 2021	CORRESP	Therapeutics Acquisition Corp. 200 Berkeley Street, 18th Floor Boston, MA 02116 Therapeutics Acquisition Corp. 200 Berkeley Street, 18th Floor Boston, MA 02116 June 8, 2021 VIA EDGAR Mr. Eric Atallah Mr. Brian Cascio Ms. Abby Adams Mr. Chris Edwards Office of Life Sciences U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Therapeutics Acquisition Corp. Acceleration Request for Registration Statement on Form S
June 7, 2021	S-4/A	Business Combination Agreement, dated as of March 15, 2021, by and among Therapeutics Acquisition Corp., Bodhi Merger Sub 1, Inc., and Point Biopharma Inc. (incorporated by reference to Annex A to the Definitive Proxy Statement filed by the Company on June 9, 2021). S-4/A 1 tm2110299-14s4a.htm S-4/A TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 4, 2021 No. 333-254600 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THERAPEUTICS ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or oth
June 4, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2021 THERAPEUTICS ACQUISITION CORP.
June 4, 2021	EX-99.1	POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC EX-99.1 2 tm2118501d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC June 4, 2021 –INDIANAPOLIS, INDIANA – POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients
June 4, 2021	EX-99.1	POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC EX-99.1 2 tm2118501d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC June 4, 2021 –INDIANAPOLIS, INDIANA – POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients
June 4, 2021	CORRESP	June 4, 2021 Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 June 4, 2021 Mr. Eric Atallah Mr. Brian Cascio Ms. Abby Adams Mr. Chris Edwards Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Therapeutics Acquisition Corp. Amendment No. 2 to Registration Statement on Form S-4 Filed May
June 4, 2021	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2021 THERAPEUTICS ACQUISITI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2021 THERAPEUTICS ACQUISITION CORP.
June 1, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2021 THERAPEUTICS ACQUISITION CORP.
June 1, 2021	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2021 THERAPEUTICS ACQUISITI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2021 THERAPEUTICS ACQUISITION CORP.
June 1, 2021	EX-99.1	POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manu EX-99.1 2 tm2118031d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility Replacing press release issued April 28, 2021 to correct ticker to RACA. Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility
June 1, 2021	EX-99.1	POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manu EX-99.1 2 tm2118031d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility Replacing press release issued April 28, 2021 to correct ticker to RACA. Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility
May 25, 2021	CORRESP	May 24, 2021 Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 May 24, 2021 Mr. Eric Atallah Mr. Brian Cascio Ms. Abby Adams Mr. Chris Edwards Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Therapeutics Acquisition Corp. Amendment No. 1 to Registration Statement on Form S-4 Filed May
May 25, 2021	S-4/A	As filed with the Securities and Exchange Commission on May 24, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 24, 2021 No.
May 10, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 THERAPEUTICS ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 THERAPEUTICS ACQUISITION CORP. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 88339T103 (CUSIP Number) MAY 4, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur
May 3, 2021	EX-10.16	Exclusive License and Commercialization Agreement, dated December 16, 2020, by and between POINT Biopharma Inc., Canadian Molecular Probe Consortium, the Centre for Probe Development and Commercialization, and the University Health Network (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-4/A filed by the Company on May 3, 2021). Exhibit 10.16 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT This Exclusive License and Commercialization Agreement (this “Agreement”), dated
May 3, 2021	EX-99.8	Consent of Dr. Rajesh K. Malik, M.D. Exhibit 99.8 CONSENT I hereby consent to serve as a director of Therapeutics Acquisition Corp. (the “Company”), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and any prospec
May 3, 2021	S-4/A	- SCHEDULE 4/A TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 30, 2021 No.
May 3, 2021	EX-10.15	Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Ari Shomair, as amended March 8, 2021. Exhibit 10.15 POINT Biopharma Corp. 22 St. Clair Ave. East, Suite 1201, Toronto, ON M4T 2S3 Ari Shomair POINT Biopharma Corp. Employment Agreement April 23, 2020 POINT Biopharma Corp. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Ari Shomair Dear Ari: Re: Terms of Employment of Ari Shomair (“you” or the “Employee”) with POINT Bio
May 3, 2021	EX-10.18	Employment Agreement, dated as of March 9, 2021, by and between POINT Biopharma Corp. and Donna Husack. EX-10.18 14 tm2110299d7ex10-18.htm EXHIBIT 10.18 Exhibit 10.18 POINT Biopharma Corp. 22 St. Clair Ave. East, Suite 1201, Toronto, ON M4T 2S3 Donna Husack POINT Biopharma Corp. Employment Agreement March 9, 2021 POINT Biopharma Corp. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Donna Husack Dear Donna: Re: Terms of Employment of
May 3, 2021	EX-10.19	Supply Agreement dated July 12, 2020, by and between POINT Biopharma Corp. and the Centre for Probe Development and Commercialization (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-4/A filed by the Company on May 3, 2021). EX-10.19 15 tm2110299d7ex10-19.htm EXHIBIT 10.19 Exhibit 10.19 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Supply Agreement – Lu-177-PNT2002 SUPPLY AGREEMENT (“Supply Agreement”) effective
May 3, 2021	EX-10.9	Employment Agreement, dated as of July 24, 2020, by and between POINT Biopharma Corp. and Bill Demers, as amended March 8, 2021 (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-4/A filed by the Company on May 3, 2021). Exhibit 10.9 POINT Biopharma Corp. 22 St. Clair Ave. East, Suite 1201, Toronto, ON M4T 2S3 William Demers POINT Biopharma Corp. Employment Agreement July 24, 2020 POINT Biopharma Corp. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL William Demers Dear William: Re: Terms of Employment of William Demers (?you? or the ?Employee?) wit
May 3, 2021	EX-10.13	Employment Agreement, dated as of July 19, 2020, by and between POINT Biopharma USA Inc. and Jessica Jensen (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-4/A filed by the Company on May 3, 2021). Exhibit 10.13 POINT Biopharma USA Inc. 4850 West 78th Street Indianapolis, Indiana 46268 United States of America POINT Biopharma USA Inc. Employment Agreement POINT Biopharma USA Inc. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Jessica Jensen Dear Jessica: Re: Terms of Employment of Jessica Jensen (?you? or the ?Employee?) wit
May 3, 2021	EX-99.9	Form of Preliminary Proxy Card Exhibit 99.9 SPECIAL MEETING OF STOCKHOLDERS THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF THERAPEUTICS ACQUISITION CORP. P R O X Y C A R D The undersigned appoints Matthew Hammond as proxy, with the power to appoint a substitute, and hereby authorizes such person to represent and to vote, as designated on the reverse side, all common stock of Therapeutics Acquisitions Corp., d/b/
May 3, 2021	EX-4.1	Specimen Certificate of Common Stock of Therapeutics Acquisition Corp. EX-4.1 2 tm2110299d7ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 SEE REVERSE FOR IMPORTANT NOTICE REGARDING OWNERSHIP AND TRANSFER RESTRICTIONS AND CERTAIN OTHER INFORMATION INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP SPECIMEN FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK. $0.0001 PAR VALUE, OF THERAPEUTICS ACQUISITION CORP. d/b/a RESEARCH ALLIANCE CORP. I transferable on the books of t
May 3, 2021	EX-10.12	Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma USA Inc. and Todd Hockemeyer. Exhibit 10.12 POINT Biopharma USA Inc. 511 South Orange Avenue, No. 2093, Newark, New Jersey, 07103 Todd Hockemeyer POINT Biopharma USA Inc. Employment Agreement April 23, 2020 POINT Biopharma USA Inc. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Todd Hockemeyer Dear Todd: Re: Terms of Employment of Todd Hockemeyer (“you” or the
May 3, 2021	EX-10.10	Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Michael Gottlieb, as amended March 8, 2021 (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-4/A filed by the Company on May 3, 2021). EX-10.10 8 tm2110299d7ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 POINT Biopharma Corp. 22 St. Clair Ave. East, Suite 1201, Toronto, ON M4T 2S3 Michael Gottlieb POINT Biopharma Corp. Employment Agreement April 23, 2020 POINT Biopharma Corp. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Michael Gottlieb Dear Michael: Re: Terms of Empl
May 3, 2021	EX-10.7	Employment Agreement, dated as of April 23, 2020, by and between POINT Biopharma Corp. and Allan Silber, as amended March 8, 2021 (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-4/A filed by the Company on May 3, 2021). EX-10.7 5 tm2110299d7ex10-7.htm EXHIBIT 10.7 Exhibit 10.7 POINT Biopharma Corp. 22 St. Clair Ave. East, Suite 1201, Toronto, ON M4T 2S3 Allan Silber POINT Biopharma Corp. Employment Agreement April 23, 2020 POINT Biopharma Corp. Employment Agreement to be effective as of and from the Effective Date (as defined below) PRIVATE AND CONFIDENTIAL Allan Silber Dear Allan: Re: Terms of Employment of Alla
May 3, 2021	EX-99.3	Consent of Dr. Yael Margolin, Ph.D. Exhibit 99.3 CONSENT I hereby consent to serve as a director of Therapeutics Acquisition Corp. (the ?Company?), if elected as such, and to be named as a nominee or potential nominee for director of the Company in any registration statement filed by the Company under the Securities Act of 1933, as amended, including all amendments and post-effective amendments or supplements thereto and any prospec

PNT / POINT Biopharma Global Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)